ctDNA monitoring test for metastatic GI cancer treatment
Part of Cancer, Digestive system clinical trials.
This trial tests whether using a ctDNA blood test along with standard CT scans can help guide treatment decisions for people with incurable metastatic gastrointestinal cancer. It may help doctors decide sooner whether a treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of digestive system cancer that has spread and cannot be cured.
- You are about to start your first or second round of systemic treatment (like chemotherapy).
- You have at least one tumor that can be measured on a CT scan.
- You had a CT scan of your chest and belly within the last 30 days.
- You are 18 years or older and able to care for yourself (ECOG score 0-2).
- Your kidney, liver, and bone marrow function are good enough for chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
This trial tests whether adjusting treatment based on a simple blood test (circulating tumor DNA) after two cycles of chemo can be safe and effective for people with advanced colorectal cancer. The goal is to tailor therapy to each person's response.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This trial uses a simple blood test to look for changes in your cancer's DNA that might show why your current treatment stopped working. The results could help your doctor choose your next treatment more precisely.
Hear when a new Gastrointestinal Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.